Inflammatory mediators in sepsis: Rationale for extracorporeal therapies?

American Journal of Kidney Diseases

Volumn 28, Issue 5 SUPPL. 3, 1996, Pages

  Jaber, Bertrand L ^a   Pereira, Brian J G ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

endotoxin; interleukin 1; Sepsis; systemic inflammatory response syndrome; tumor necrosis factor

Indexed keywords

ARGININE; CYTOKINE; ENDOTOXIN; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; INTERLEUKIN 4; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; POLYCLONAL ANTIBODY; SOMATOSTATIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; EXTRACORPOREAL CIRCULATION; GRAM NEGATIVE INFECTION; HEMOFILTRATION; HEMOPERFUSION; HUMAN; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PLASMAPHERESIS; SEPSIS;

EID: 0029990845     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(96)90078-5     Document Type: Article

References (137)

1. American College of Chest Physicians-Society of Critical Care Medicine Consensus Conference: Definitions of sepsis and organ failure and guidelines for the use of innovative therapies is sepsis. Crit Care Med 20:864-874, 1992
2. Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA Jr, O'Connor JV: Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1. J Exp Med 163:1433-1450, 1986
3. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA: Interleukin-1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81:1162-1172, 1988
4. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP: The natural history of the systemic inflammatory response syndrome. JAMA 273:117-123, 1995
5. Center for Disease Control: Increases in national hospital discharge survey rates for septicemia - United States, 1979-1987. MMWR 39:31-34, 1990
6. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP: Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 113:227-242, 1990
7. Parrillo JE: Management of septic shock: Present and future. Ann Intern Med 115:491-493, 1991
8. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 328:1471-1477, 1993
9. Billiau A, Vandekerckhove F: Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shock. Eur J Clin Invest 21:559-573, 1991
10. Dinarello CA, Gelfand JA, Wolff SM: Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA 269:1829-1835, 1993
11. Natanson C, Hoffman WD, Suffredini AF, Eichacker PQ, Danner RL: Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 120:771-783, 1994
12. Hoffman WD, Natanson C: Endotoxin in septic shock. Anesth Analg 77:613-624, 1993
13. Westphal O, Jann K, Himmelspach K: Chemistry and immunochemistry of bacterial lipopolysaccharide as cell wall antigens and endotoxins. Prog Allergy 33:9-39, 1983
14. Galanos C, Luderitz O, Rietschel ET, Wetsphal O, Brade H, Brade L, Freudenberg M, Scande U, Imoyo M, Yoshimura H: Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem 148:1-5, 1985
15. Riveau GR, Novitsky TJ, Roslansky PF, Dinarello CA, Warren HS: Role of interleukin-1 in augmenting serum neutralization of bacterial lipopolysaccharide. J Clin Microbiol 25:889-892, 1987
16. Opal SM, Palardy JE, Marra MN, Fisher CJJ, McKelligon BM, Scott RW: Relative concentrations of endotoxinbinding proteins in body fluids during infection. Lancet 344:429-431, 1994
17. Bone RC: The pathogenesis of sepsis. Ann Intern Med 115:457-460, 1991
18. Morrison DC, Ryan JL: Endotoxins and disease mechanisms. Annu Rev Med 38:41-432, 1987
19. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes for lipopolysaccharide (LPS) and LPS-binding protein. Science 249:1431-1433, 1990
20. Mathison JC, Wolfson E, Steinmann S, Tobias PS, Ulevitch RJ: Lipopolysaccharide (LPS) recognition in macrophages. Participation of LPSbinding protein and CD14 in LPS-induced adaptation in rabbit peritoneal exudate macrophages. J Clin Invest 92:2053-2059, 1992
21. Tobias PS, Soldan K, Ulevitch RJ: Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem 284:10867-10871, 1989
22. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ: Structure and function of lipopolysaccharide binding protein. Science 249:1429-1431, 1990
23. Ramadori G, Meyer ZUM, Buschenfeld KH, Tobias PS, Mathison JC, Ulevitch RJ: Biosynthesis of lipopolysaccharide-binding protein in rabbit hepatocytes. Pathobiology 58:89-94, 1990
24. Pereira HA, Spiznagel JK, Winton EF, Winton EF, Shafer WM, Martin LE, Guzman GS, Pohl J, Scott RW, Marra MN, Kinkade JM Jr: The ontogeny of a 57-Kd cationic antimicrobial protein of human polymorphonuclear leukocytes: Localization to a novel granule protein. Blood 76:825-834, 1990
25. Marra MN, Wilde CG, Collins MS, Snable JL, Thornton MB, Scott RW: The role of bactericidal/permeability-increasing protein as a natural inhibitor of bacterial endotoxin. J Immunol 148:532-537, 1992
26. Gray PW, Flaggs G, Leong SR, Gumina RJ, Weiss J, Ooi CE, Elsbach P: Cloning of the cDNA of a human neutrophil bactericidal protein. J Biol Chem 264:9595-9599, 1989
27. Hoes A, Watson S, Siber G, Liddington R: Crystal structure of an endotoxin- neutralizing protein from the horseshoe crab, limulus-anti-lipopolysaccharide factor, at 1.5 A resolution. Eur Mol Biol Org 12:3351-3356, 1993
28. Mathison JC, Tobias PS, Wolfson E, Ulevitch RJ: Plasma lipopolysaccharide (LPS)-binding protein, a key component in macrophage recognition of gramnegative LPS. J Immunol 149:200-206, 1992
29. Marra MN, Wilde CG, Collins MS, Snable JL, Scott RW: Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J Immunol 144:662-666, 1990
30. Weiss J, Elsbach P, Shu C, Castillo J, Grinna L, Horwitz A, Theofan G: Human bactericidal/permeability-increasing protein and a recombinant NH 2 -terminal fragment cause killing of serum-resistant, gram-negative bacteria in whole blood and inhibit tumor necrosis factor release by the bacteria. J Clin Invest 90:1122-1130, 1992
31. Heumann D, Galley P, Betz-Corradin S, Barras C, Baumgartner JD, Glauser MP: Competition between bactericidal/permeability-increasing and lipopolysaccharide-binding protein for lipopolysaccharide binding to monocytes. J Infect Dis 176:1351-1357, 1993
32. Mechanic RC, Frei III E, Landy M, Smith WW: Quantitative studies of human leukocytic and febrile response to single and repeated doses of purified bacterial endotoxin. J Clin Invest 41:162-172, 1962
33. Wolff SM, Rubenstein JH, Mulholland JH, Ailing DW: Comparison of hematologic and febrile response to endotoxin in man. Blood 26:190-201, 1965
34. Suffredini AF, Fromm RE, Parker M, Brenner M, Kovacs JA, Wesley RA, Parrillo JE: The cardiovascular response of normal humans to administration of endotoxin. N Engl J Med 321:280-287, 1989
35. Suffredini AF, Harpel PC, Parillo JE: Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 320:1165-1172, 1989
36. O'Dwyer ST, Michie HR, Ziegler TR, Revhaug A, Smith RJ, Wilmore DW: A single dose of endotoxin increases intestinal permeability in healthy humans. Arch Surg 123:1459-1464, 1988
37. Casale TB, Ballas ZK, Kaliner MA, Keahey TM: The effect of intravenous endotoxin on various host-effector molecules. J Allergy Clin Immunol 85:45-51, 1990
38. Richardson RP, Ryne CD, Pong Y, Hesse DG, Tracey KJ, Marano MA, Lowry SF, Antonacci AC, Calvano SE: Peripheral blood leukocyte kinetics following in vivo lipopolysaccharide (LPS) administration to normal human subjects. Influence of elicited hormones and cytokines. Ann Surg 210:239-245, 1989
39. Martich GD, Danner RL, Ceska M, Suffredini AF: Detection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxin: The effect of anti-inflammatory agents. J Exp Med 173:1021-1024, 1991
40. Granowitz EV, Santos A, Poutsiaka DD, Cannon JG, Wilmore DA, Wolff SM, Dinarello CA: Production of interleukin-1 receptor antagonist during experimental endotoxemia. Lancet 338:1423-1424, 1991
41. Shapiro L, Clark BD, Orencole SF, Poutsiaka DD, Granowitz EV, Dinarello CA: Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis 167:1344-1350, 1993
42. Reinhold R, Fine J: A technique for quantitative measurement of endotoxin in human plasma. Proc Soc Exp Biol Med 137:334-340, 1971
43. Levin J, Poore TE, Zauber NP, Oser RS: Detection of endotoxin in the blood of patients with sepsis due to gramnegative bacteria. N Engl J Med 283:1313-1316, 1970
44. Elin RJ, Robinson RA, Levine AS, Wolff SM: Lack of clinical usefulness of the limulus test in the diagnosis of endotoxemia. N Engl J Med 293:521-523, 1975
45. Thomas LLM, Sturk A, Kahle LH, Ten Cate JW: Quantitative endotoxin determination in blood with a chromogenic substrate. Clin Chem Acta 16:63-68, 1981
46. Thomas LL, Sturk A, Buller HR, ten Cate JW, Spijker RE, ten Cate H: Comparative investigation of a quantitative chromogenic endotoxin assay and blood cultures. Am J Clin Pathol 82:203-206, 1984
47. Natanson C, Danner RL, Reilly JM, Doerfler ML, Hoffman WD, Akin GL, Hosseini JM, Banks SM, Elin RJ, MacVittie TJ, Parrillo JE: Antibiotics versus cardiovascular support in a canine model of human septic shock. Am J Physiol 259:H1440-1447, 1990
48. Danner RL, Natanson C, Elin RJ, Hosseini JM, Banks S, MacVittie TJ, Parrillo JE: Pseudomonas aeruginosa compared with Escherichia coli produces less endotoxemia but more cardiovascular dysfunction and mortality in a canine model of septic shock. Chest 98:1480-1487, 1990
49. Natanson C, Danner RL, Elin RJ, Hosseini JM, Peart KW, Banks SM, MacVittie TJ, Walker RI, Parrillo JE: Role of endotoxemia in cardiovascular dysfunction and mortality: Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest 83:243-251, 1989
50. Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE: Endotoxemia in human septic shock. Chest 99:169-176, 1991
51. Elin RJ: Clinical utility of the limulus test with blood, CSF, and synovial fluid, in Cohen E, Bang FB, Levin J, Marchalonis JJ, Pistoli TG, Prendergast RA, Shuster C Jr, Watson SW (eds): Biomedical Applications of the Horseshoe Crab (Limulidae). New York, NY, Liss AR, 1979, pp 279-292
52. Fink MP: Why the GI tract is pivotal in trauma, sepsis, and MOF. J Crit Illness 6:253-273, 1991
53. Deitch EA: Simple intestinal obstruction causes bacterial translocation in man. Arch Surg 124:699-701, 1989
54. Rush BFJ, Sori AJ, Murphy TF, Smith S, Flanagan JJJ, Machiedo GW: Endotoxemia and bacteremia during hemorrhagic shock: The link between trauma and sepsis? Ann Surg 207:549-554, 1988
55. Jacob JI, Golberg PK, Bloom N, Degenshein GA, Kozinn PJ: Endotoxin and bacteria in portal blood. Gastroenterology 72:1268-1270, 1977
56. Ikejima T, Okusawa S, va der Meer JW, Dinarello CA: Induction by toxic-shock- syndrome toxin-1 of a circulating tumor necrosis factor-like substance in rabbits and of immunoreactive tumor necrosis factor and interleukin-1 from human mononuclear cells. J Infect Dis 158:1017-1025, 1988
57. Hackett SP, Stevens DL: Streptococcal toxic shock syndrome: Synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 165:879-885, 1992
58. Stephenson J: Reflecting and regrouping after failed trials, sepsis researchers forge on. JAMA 275:823-824, 1996
59. Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 77:1627-1652, 1991
60. Dayer JM, Beutler B, Cerami A: Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 162:2163-2168, 1985
61. Perlmutter DH, Dinarello CA, Punsal PI, Colten HR: Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest 78:1349-1354, 1986
62. Dinarello CA: Role of interleukin-1 in infectious diseases. Immunol Rev 127:119-146, 1992
63. Hack CE, DeGroot ER, Felt-Bersma RJF, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA: Increased plasma levels of interleukin-6 in sepsis. Blood 74:1704-1710, 1989
64. Baggiolini M, Dewald B, Waltx A: Interleukin-8 and related cytokines, in Gallin JI, Goldstein IM, Synderman R (eds): Inflammation: Basic Principles and Clinical Correlates. New York, NY, Raven, 1992, pp 247-263
65. Dejana E, Breviaro F, Erroi A, Bussolino F, Mussoni L, Gramse M, Pintucci G, Casali B, Dinarello CA, Van Damme J, Mantovani A: Modulation of endothelial cell functions by different molecular species of interleukin-1. Blood 69:695-699, 1987
66. Mizogushi Y, Ichikawa Y, Kioka K, Kawada N, Kobayashi K, Yamamoto S: Effetcs of arachidonic acid metabolites and interleukin-1 on platelet activating factor production by hepatic sinusoidal endothelial cells from mice. J Gastroenterol Hepatol 6:283-288, 1991
67. Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 316:379-385, 1987
68. Dinarello CA: Interleukin-1 and its biologically related cytokines. Adv Immunol 44:153-205, 1989
69. Christman JW: Potential treatment of sepsis syndrome with cytokine-specific agents. Chest 102:613-617, 1992
70. Cannon JG, Friedberg JS, Gelfand JA, Tompkins RG, Burke JF, Dinarello CA: Circulating interleukin-1β and tumor necrosis factor-a after burn injury in humans. Crit Care Med 20:1414-1419, 1992
71. Michie HR, Manogue KR, Spriggs DR, Bevhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481-1486, 1988
72. Cannon JG, Thompkins RG, Gelfand JA, Michie HR, Stanford GG, van der Meer JW, Endres S, Lonnemann G, Corsetti J, Chernow R, Wilmore DW, Wolff SM, Burke JF, Dinarello CA: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79-84, 1990
73. Endres S, Cannon JG, Ghorbani R, Dempsey RA, Sisson SD, Lonnemann G, van der Meer JWM, Wolff SM, Dinarello CA: In vitro production of IL-1b, IL-1a, TNF, and IL-2 in healthy subjects: Distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol 19:2327-2333, 1989
74. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA: Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 78:1275-1281, 1991
75. Dinarello CA: The role of interleukin-1 in disease. N Engl J Med 328:106-113, 1993
76. Ginsberg HS, Moldawer LL, Sehgal PB, Redington M, Kilian PL, Chanock RM, Prince GA: A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci USA 88:1651-1655, 1991
77. Engelmann H, Novick D, Wallach D: Two tumor necrosis factor-binding proteins purified from human urine: Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265:1531-1536, 1990
78. Symons JA, Eastgate JA, Duff GW: Purification and characterization of a novel soluble receptor for interleukin-1. J Exp Med 174:1251-1254, 1991
79. Cannon JG, Dinarello CA: Multiple interleukin-1 activities in luteal phase human plasma. Brit J Rheumatol 24:226-229, 1985
80. Dinarello CA: ELISA kits based on monoclonal antibodies do not measure total IL-1β synthesis. J Immunol Methods 148:255-259, 1992
81. Cannon JG, Nerad JL, Poutsiaka DD, Dinarello CA: Measuring circulating cytokines. J App Physiol 5:1897-1902, 1993
82. Borth W, Urbanski A, Prohaska R, Susanj M, Luger TA: Binding of recombinant interleukin-1β to the third complement and α-2-macroglobulin after activation of serum by immune complexes. Blood 75:2388-2395, 1990
83. Parker MM, Shelhamer JH, Natanson C, Alling DW, Parillo JE: Serial cardiovascular variables in survivors and nonsurvivors in human septic shock: Heart rate as an early predictor of prognosis. Crit Care Med 15:923-929, 1987
84. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100:483-490, 1984
85. Parker M, McCarthy KE, Ognibene FP, Parillo JE: Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 97:126-131, 1990
86. Parker MM, Suffredini AF, Natanson C, Ognibene FP, Shelhamer JH, Parillo JE: Responses of left ventricular function in survivors and nonsurvivors of septic shock. J Crit Care 4:19-25, 1989
87. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parillo JE: The coronary circulation in human septic shock. Circulation 73:637-644, 1986
88. Parrillo JE, Burch C, Shelhamer JH, Natanson C, Schuette W: A circulating myocardial depressant substance in humans with septic shock: Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 76:1539-1553, 1985
89. 2+ current in cardiomyocytes. Am J Physiol 29:H869-H876, 1991
90. Kumar A, Dimou C, Hollenberg SM: Tumor necrosis factor produces a concentration-dependent depression of myocardial cell contraction in vitro. Clin Res 39:321A, 1991 (abstr)
91. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257:387-389, 1992
92. Munford RS: Sepsis and septic shock, in Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Hasper DL (eds): Harrison's Principles of Internal Medicine. New York, NY, McGraw-Hill,1994, pp 511-515
93. Young LS: Sepsis syndrome, in Mandell GL, Bennett JE, Dolin R (eds): Principles and Practice of Infectious Diseases. New York, NY, Churchill Livingstone, 1995, pp 690-705
94. Sagawa T, Hitsumoto Y, Kanon M, Utsumi S, Kimura S: Mechanisms of neutralization of endotoxin by monoclonal antibodies to O and R determinants of lipopolysaccharide. Adv Exp Med Biol 256:341-344, 1990
95. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI: Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307:1225-1230, 1982
96. Baumgartner JD, Glauser MP, McCutchan JA, Ziegler EJ, van Meile G, Klauber MR, Vogt M, Muehlen E, Luethy R, Chiolero R, Geroulanos S: Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 2:59-63, 1985
97. J5 Study Group: Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli 35: A prospective double-blind study. J Infect Dis 165:695-701, 1992
98. Calandra T, Glauser MP, Schellekens J, Verhoef J: Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 158:312-319, 1988
99. The Intravenous Immunoglobulin Collaborative Study Group: Prophylactic intravenous administration of standard immune globulin as compared with core- lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 327:2334-2340, 1992
100. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmauel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, Russell JA, the XOMA Sepsis Study Group: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266:1097-1102, 1991
101. Ziegler EJ, Fisher CJJ, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NNH, Allen IE, Berger HJ, Knatterud GL, LoBuglio AF, Smith GR, the HA-1A Sepsis Study Group: Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429-436, 1991
102. Warren HS, Danner RL, Munford RS: Sounding board: Antiendotoxin antibodies. N Engl J Med 266:1153-1157, 1992
103. Quezado ZMN, Natanson C, Ailing DW, Banks SM, Koev CA, Elin RJ, Hosseini JM, Bacher JD, Danner RL, Huffman WD: A controlled trial of a human lipid A-reactive monoclonal antibody, HA-1A, in a canine model of gramnegative septic shock. JAMA 269:2221-2227, 1993
104. Luce JM: Introduction of new technology into critical care practice: A history of HA-1A human monoclonal antibody against endotoxin. Crit Care Med 21:1233-1241, 1993
105. Wisniewski MA, Kazemi M, Fang IS, Knight LS, Huntenburg CC, Bubbers JE, Schneidkraut MJ: Comparison of binding specificity and the function of two human IgM anti-lipid A monoclonal antibodies. Circ Shock 44:230-237, 1994
106. Marx J: How the glucocorticoids suppress immunity. Science 270:232-233, 1995
107. Auphan N, Didonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: Inhibition of NF-kB activity through induction of IkB synthesis. Science 270:286-290, 1995
108. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin ASJ: Role of transcriptional activation of IkBa in mediation of immunosuppression by glucocorticoids. Science 270:283-286, 1995
109. Han J, Thompson P, Beutler B: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172:391-394, 1990
110. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz GA, Balk RA, the Methylprednisolone Severe Sepsis Study Group: A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653-658, 1987
111. The Veterans Administration Systemic Sepsis Cooperative Study Group: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317:659-665, 1987
112. Stricter RM, Remick DG, Ward PA: Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 155:1230-1236, 1988
113. Doherty GM, Jensen JC, Alexander H, Buresh CM, Norton JA: Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 110:192-198, 1991
114. Balibrea JL, Arias-Diaz J, Garcia C, Vara E: Effect of pentoxifylline and somatostatin on tumor necrosis factor production by human pulmonary macrophages. Circ Shock 43:51-56, 1994
115. Bermudez LE, Wu M, Young LS: Effect of stress-related hormones on macrophage receptors and response to tumor necrosis factor. Lymphokine Res 9:137-145, 1990
116. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J Exp Med 173:699-703, 1991
117. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J Exp Med 177:1675-1680, 1993
118. Barbul A: Arginine: Biochemistry, physiology, and therapeutic implications. J Parenteral and Enterai Nutrition 10:227-238, 1986
119. Gallery MP, Mangino MJ, Flye W: A biologic basis for limited Kupfer cell reactivity to portal-derived endotoxin. Surgery 110:221-230, 1991
120. Druml W: Impact of continuous renal replacement therapies on metabolism. J Intern Artif Organs 19:118-120, 1996
121. Silva AT, Bayston KF, Cohen J: Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor in experimental gram-negative shock. J Infect Dis 162:421-427, 1990
122. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, Lowry SF, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330:662-664, 1987
123. Hinshaw LB, Tekamp-Olson P, Chang ACK, Lee PA, Taylor FB Jr, Murray CK, Peer GT, Emerson TE Jr, Passey RB, Kuo GC: Survival of primates in LD 100 septic shock following therapy with antibody to tumor necrosis factor (TNFα). Circ Shock 30:279-292, 1990
124. Jesmok GJ, Lindsey DC, Duerr ML, Fournel MA, Emerson TEJ: Efficacy of monoclonal antibody against human recombinant TNF in E. coli challenged swine. Am J Pathol 141:1197-1207, 1992
125. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC, for the TNF-α Mab Sepsis Study Group: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis syndrome. JAMA 273:934-941, 1995
126. Mohler KM, Torrance DS, Smith CA, Goodwin RG, Stremler KE, Fung VP, Madani H, Widmer MB: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548-1561, 1993
127. Ding AH, Sanchez E, Srimal S, Nathan CF: Macrophages rapidly internalize their tumor necrosis factor receptors in response to bacterial lipopolysaccharide. J Biol Chem 264:3924-3929, 1989
128. Spinas GA, Keller U, Brockhaus M: Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF experimental endotoxinemia. J Clin Invest 90:533-536, 1992
129. Goldie AS, Fearon KCH, Ross JA, Barclay GR, Jackson RE, Grant IS, Ramsay G, Blyth AS, Howie JC, for the Sepsis Intervention Group: Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 274:172-177, 1995
130. Seckinger P, Lowenthal JW, Williamson K, Dayer JM, MacDonald HR: A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 139:1546-1549, 1987
131. Dinarello CA, Thompson RC: Blocking IL-1: Effects of IL-1 receptor antagonist in vitro and in vivo. Immunol Today 12:404-410, 1991
132. Fisher CJJ, Dhainaut JFA, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberi TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson BW, La-Brecque JF, Catalano MA, Knauss WA, Sadoff JC, for the Phase III rhIL-1Ra Sepsis Syndrome Study Group: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 271:1836-1843, 1994
133. Cerretti DP, Kozlosky CJ, Mosley B, Nelson N, Ness KV, Greenstreet TA, March CJ, Kronheim SR, Druck T, Cannizzaro LA, Huebner K, Black RA: Molecular cloning of the interleukin-1β converting enzyme. Science 256:97-100, 1992
134. Von Asmuth EJU, Van der Linden CJ, Leeuwenberg JFM, Buurman WA: Involvement of the CD11b/CD18 integrin, but not of the endothelial cell adhesion molecules ELAM-1 and ICAM-1 in tumor necrosis factor-α-induced neutrophil toxicity. J Immunol 147:3869-3875, 1991
135. Eichacker PQ, Hoffman WD, Farese A, Danner RL, Suffredini AF, Waisman Y, Banks SM, Mouginis T, Wilson L, Rothlein R, Elin RJ, Hosseini JM, MacVittie TJ, Natanson C: Leukocyte CD18 monoclonal antibody worsens endotoxemia and cardiovascular injury in canines with septic shock. J Appl Physiol 74:1885-1892, 1993
136. Eickhacker PO, Hammond W, Farese A, Hoffman WD, Danner RL, Banks SM, MacVittie T, Natanson C: Serial serum granulocyte colony stimulating factor levels in a canine model of bacterial sepsis. Clin Res 41:240A, 1993 (abstr)
137. Perl TM, Dvorak L, Hwang T, Wenzel RP: Long-term survival and function after suspected gram-negative sepsis. JAMA 274:338-345, 1995